Sunshine Biopharma Inc. (SBFM) Stock Price & Analysis

Sunshine Biopharma Inc. (SBFM) rose 1.32% to USD 1.15 as of September 8, 2026 at 22:17 UTC, according to Nexqual real-time market data.

SBFM last closed at USD 1.15; the session ranged USD 1.14–1.24 on volume of 287,806 shares. Market capitalization is —, with a 52-week range of USD 1.01–24.3 (NCM). Source: Nexqual, September 8, 2026 at 22:17 UTC.

Key Statistics (as of September 8, 2026 at 22:17 UTC)

Technical Analysis (SBFM)

Nexqual's technical model rates SBFM "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 22:17 UTC.

From Sunshine Biopharma Inc.'s Latest SEC 10-K Filing (filed 2026-04-03)

Key Strengths & Strategy (as disclosed to the SEC)

• As of the date of the filing of this report, we have not made any filings with the FDA or other regulatory bodies in other jurisdictions in connection with our proprietary drugs in development.   In respect of OTC supplements, the FDA regulates the formulation, manufacturing, packaging, storage, labeling, promotion, distribution, and sale of such products, while the Federal Trade Commission ("FTC") regulates marketing and advertising claims.
• Our personnel, together with outside consultants develop and place ads on various media platforms and manage our Amazon.ca account.             Competition   According to IMARC Group , the Canadian generic pharmaceuticals market was valued at approximately $10.4 billion USD in 2024 and is expected to grow to $19.7 billion USD by 2033.
• As of the date of this report, we believe Essential•9™ is the only Essential Amino Acid supplement that comprises all 9 essential amino acids in capsule form.   Workforce   As of the date of this report, we have a total of 50 employees, all of whom are full-time.   Presently, our proprietary drug development activities are subcontracted out to specialized service providers in the U.S., Canada and overseas.

Partnerships

• On April 20, 2022, we filed a provisional patent application in the United States covering our K1.1 mRNA molecules.           In November 2022, we concluded an agreement with a specialized commercial partner for the purposes of formulating our K1.1 mRNA molecules into specific lipid nanoparticles for use in test animals including xenograft mice.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 22:17 UTC. This page is informational and not investment advice.